A highly anticipated announcement Monday from the companies Pfizer and BioNTech revealed that their lower-dose Covid-19 vaccine was found to be safe and generated a “robust” antibody response in children ages 5 to 11, based on data from a Phase 2/3 trial.
A highly anticipated announcement Monday from the companies Pfizer and BioNTech revealed that their lower-dose Covid-19 vaccine was found to be safe and generated a “robust” antibody response in children ages 5 to 11, based on data from a Phase 2/3 trial.
